Eton Pharmaceuticals Shares Skyrocket 30% in 6 Days Since Baylor Deal to Advance ET-900
Eton Pharmaceuticals (ETON) partners with Baylor College of Medicine to develop ET-900 for infantile spasms, targeting a Phase 2 trial launch in Q1 2027.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Eton Pharmaceuticals, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (2 Nov 2026). Not a valuation or a recommendation.
Up 29.8% over the last month ($49.22 on 19 Oct → $63.88 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $49.22 |
|---|---|
| 20 Oct | $50.19 |
| 21 Oct | $49.30 |
| 22 Oct | $50.02 |
| 23 Oct | $50.00 |
| 26 Oct | $50.17 |
| 27 Oct | $51.16 |
| 28 Oct | $51.80 |
| 29 Oct | $53.67 |
| 30 Oct | $52.18 |
| 2 Nov | $50.81 |
| 3 Nov | $50.95 |
| 4 Nov | $50.72 |
| 5 Nov | $47.15 |
| 6 Nov | $56.46 |
| 9 Nov | $64.35 |
| 10 Nov | $67.54 |
| 11 Nov | $68.40 |
| 12 Nov | $61.45 |
| 13 Nov | $63.93 |
| 16 Nov | $63.88 |
Eton Pharmaceuticals (ETON) partners with Baylor College of Medicine to develop ET-900 for infantile spasms, targeting a Phase 2 trial launch in Q1 2027.
Eton Pharmaceuticals acquires exclusive U.S. rights to LIBERVANT from Aquestive for $10M upfront, targeting the $450M annual seizure rescue treatment market.
Track Eton Pharmaceuticals, Inc. live
Get the next Eton Pharmaceuticals, Inc. SEC filing seconds after it lands.